This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis
by Zacks Equity Research
Novartis' (NVS) psoriasis drug, Cosentyx is already approved for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.
Top Research Reports for Novartis, BP & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), BP (BP) and Biogen (BIIB).
Array's Melanoma Combo Shows Positive Overall Survival Data
by Zacks Equity Research
Array's (ARRY) shares gain on impressive overall survival data from a phase III trial of combined binimetinib and encorafenib for BRAF-mutant advanced, unresectable or metastatic melanoma.
Roche Reports Positive Data From Tecentriq-Avastin Study
by Zacks Equity Research
Roche reported positive results from a phase III study on the combination of immunotherapy drug Tecentriq and oncology drug Avastin.
Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft
by Zacks Equity Research
Amgen (AMGN) misses expectations for both earnings and sales and also issues a lower-than-expected sales guidance for 2018. Shares decline in after-hours trading.
Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might lead the company to an earnings beat in Q4.
Roche (RHHBY) Posts Solid 2017 Sales on Tecentriq & Alecensa
by Zacks Equity Research
Roche reported strong sales for 2017 buoyed by performance of new drugs ??? Tecentriq, Alecensa and Perjeta which offset the decline in Tarceva and Avastin.
Momenta Up on FDA's Amendment of McPherson Compliance Status
by Zacks Equity Research
Momenta's (MNTA) stock gains as investors were relieved after the FDA classified the outcome of fourth-quarter 2017 reinspection of Pfizer's McPherson facility as Voluntary Action Indicated.
Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX
by Zacks Equity Research
Two pharma/biotech giants are scheduled to report earnings on Jan 31. Let's take a look at how the companies are placed ahead of the upcoming releases.
Roche Gets Breakthrough Therapy Designation For ASD Drug
by Zacks Equity Research
Roche obtains Breakthrough Therapy Designation for its experimental drug oral medicine balovaptan from the FDA which is likely to expedite the review and development of the drug.
Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors
by Zacks Equity Research
Novartis' oncology portfolio gets a further boost with the FDA approval of Lutathera for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.
Roche Hemophilia Drug Hemlibra Gets Positive CHMP Opinion
by Zacks Equity Research
Roche announced that it its hemophilia drug Hemlibra obtained a positive opinion from the Committee for Medicinal Products for Human Use in Europe.
Foreign Stock Roundup: Novartis, UBS & Posco Results Impress, Sanofi Buys Bioverativ
by Swarup Gupta
The government shutdown in the United States guided stocks across Europe and Asia last week.
Novartis Gets Spark Therapeutics' Luxterna License Outside US
by Zacks Equity Research
Novartis has obtained the marketing rights for Luxterna oustide the United States thereby building upon its gene therapy treatments which includes Kymriah.
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
by Zacks Equity Research
Novartis (NVS) announced strong results for the fourth quarter as earnings and sales both beat estimates driven by Cosentyx and Entresto sales which more than offset the decline in Gleevec sales.
Novartis Announces Positive Results on Migraine Candidate
by Zacks Equity Research
Novartis announced positive results on migraine candidate, AMG334, from the phase IIIb study. The candidate is being developed in collaboration with Amgen,
Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb
by Zacks Equity Research
Amgen's (AMGN) antibody Aimovig meets all primary and secondary endpoints in a phase IIIb study on patients with episodic migraine, who have failed multiple prior preventive treatments.
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
by Zacks Equity Research
Teva's (TEVA) two phase III studies evaluating the subcutaneous formulation of its asthma injection, Cinqair (reslizumab) fail to meet primary endpoints.
What's in the Cards for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Novartis has an excellent track record. We expect investors to focus on the performance of new drugs and revival of Alcon business.
Gilead Collaborates with Pfizer for Yescarta Combo Study
by Zacks Equity Research
Kite, a Gilead Company (GILD), announced that it inked a clinical trial collaboration with Pfizer, for combination study.
Pharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label Expansion
by Arpita Dutt
Focus this week was on Merck's (MRK) data on Keytruda as well as Novartis's updates on Kymriah and its biosimilar efforts.
Juno Hits 52-Week High on Celgene's Rumored Buyout Interest
by Zacks Equity Research
Juno Therapeutics, Inc.'s (JUNO) shares hit a 52 week high on rumors of the company being acquired by Celgene Corporation.
Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA
by Zacks Equity Research
Novartis (NVS) gets a significant boost with the FDA approval of CAR-T Therapy Kymriah and the company is now looking to expand the therapy's label.
3 Top-Ranked Drug Stocks that are Broker Favorites
by Arpita Dutt
With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.
3 Biotech Stocks Start Healthy in '18: Will the Rally Last?
by Zacks Equity Research
We take a look at some biotech stocks that have witnessed an increase in their share price this year so far and look well positioned for the rest of 2018.